{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:55:43Z","timestamp":1790369743897,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.diabres.2026.113404","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:27:28Z","timestamp":1782923248000},"page":"113404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes"],"prefix":"10.1016","volume":"238","author":[{"given":"Yuki","family":"Kokura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9639-5470","authenticated-orcid":false,"given":"Takefumi","family":"Kishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8213-7999","authenticated-orcid":false,"given":"Takao","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7824-3056","authenticated-orcid":false,"given":"Osamu","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113404_b0005","doi-asserted-by":"crossref","unstructured":"Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev 2017;7-11. https:\/\/doi: 10.15420\/cfr.2016:25:2.","DOI":"10.15420\/cfr.2016:25:2"},{"key":"10.1016\/j.diabres.2026.113404_b0010","doi-asserted-by":"crossref","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al.; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. Circ J 2025;89:1278-1444. https:\/\/doi: 10.1253\/circj.CJ-25-0002.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"10.1016\/j.diabres.2026.113404_b0015","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.; ACC\/AHA Joint Committee Members. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-e1032. https:\/\/doi: 10.1161\/CIR.0000000000001063. Erratum in: Circulation 2022;145:e1033. https:\/\/doi: 10.1161\/CIR.0000000000001073. Erratum in: Circulation 2022;146:e185. https:\/\/doi: 10.1161\/CIR.0000000000001097. Erratum in: Circulation 2023;147:e674. https:\/\/doi: 10.1161\/CIR.0000000000001142.","DOI":"10.1161\/CIR.0000000000001142"},{"key":"10.1016\/j.diabres.2026.113404_b0020","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627-39. https:\/\/doi: 10.1093\/eurheartj\/ehad195. Erratum in: Eur Heart J 2024;45:53. https:\/\/doi: 10.1093\/eurheartj\/ehad613.","DOI":"10.1093\/eurheartj\/ehad613"},{"key":"10.1016\/j.diabres.2026.113404_b0025","doi-asserted-by":"crossref","unstructured":"MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, et al.; Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-40. https:\/\/doi: 10.1093\/eurheartj\/ehn156.","DOI":"10.1093\/eurheartj\/ehn156"},{"key":"10.1016\/j.diabres.2026.113404_b0030","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-22. https:\/\/doi: 10.1056\/NEJMoa1603827.","DOI":"10.1056\/NEJMoa1603827"},{"key":"10.1016\/j.diabres.2026.113404_b0035","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30. https:\/\/doi: 10.1016\/S0140-6736(19)31149-3.","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"10.1016\/j.diabres.2026.113404_b0040","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-44. https:\/\/doi: 10.1056\/NEJMoa1607141.","DOI":"10.1056\/NEJMoa1607141"},{"key":"10.1016\/j.diabres.2026.113404_b0045","doi-asserted-by":"crossref","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2023;389:1069-84. https:\/\/doi: 10.1056\/NEJMoa2306963.","DOI":"10.1056\/NEJMoa2306963"},{"key":"10.1016\/j.diabres.2026.113404_b0050","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-32. https:\/\/doi: 10.1056\/NEJMoa2307563.","DOI":"10.1056\/NEJMoa2307563"},{"key":"10.1016\/j.diabres.2026.113404_b0055","doi-asserted-by":"crossref","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al.; NHLBI Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2016;316:500-8. https:\/\/doi: 10.1001\/jama.2016.10260.","DOI":"10.1001\/jama.2016.10260"},{"key":"10.1016\/j.diabres.2026.113404_b0060","doi-asserted-by":"crossref","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, et al. ;Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69-77. https:\/\/doi: 10.1002\/ejhf.657.","DOI":"10.1002\/ejhf.657"},{"key":"10.1016\/j.diabres.2026.113404_b0065","unstructured":"TriNetX network overview: Bowe B et al., The 2019 Novel Coronavirus Disease (COVID-19) Pandemic: Use of the TriNetX Network for Observational Studies, J Med Internet Res 2020;22:e22119."},{"key":"10.1016\/j.diabres.2026.113404_b0070","doi-asserted-by":"crossref","unstructured":"Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, et al.; Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes. Sci Rep 2025;15:21333. https:\/\/doi: 10.1038\/s41598-025-06245-w.","DOI":"10.1038\/s41598-025-06245-w"},{"key":"10.1016\/j.diabres.2026.113404_b0075","doi-asserted-by":"crossref","unstructured":"Modzelewski KL, Pipilas A, Bosch NA. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open 2024;7:e249305. https:\/\/doi: 10.1001\/jamanetworkopen.2024.9305. Erratum in: JAMA Netw Open 2024;7:e2428489. https:\/\/doi: 10.1001\/jamanetworkopen.2024.28489.","DOI":"10.1001\/jamanetworkopen.2024.9305"},{"key":"10.1016\/j.diabres.2026.113404_b0080","doi-asserted-by":"crossref","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al.; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes N Engl J Med. 2025;392:2001-12. https:\/\/doi: 10.1056\/NEJMoa2501006.","DOI":"10.1056\/NEJMoa2501006"},{"key":"10.1016\/j.diabres.2026.113404_b0085","doi-asserted-by":"crossref","unstructured":"Horiuchi Y, Asami M, Yahagi K, Oshima A, Gonda Y, Yoshiura D, et al.; Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia. J Clin Med 2024;13:1670. https:\/\/doi: 10.3390\/jcm13061670.","DOI":"10.3390\/jcm13061670"},{"key":"10.1016\/j.diabres.2026.113404_b0090","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commum Stat - Simul Comput"},{"key":"10.1016\/j.diabres.2026.113404_b0095","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.diabres.2026.113404_b0100","doi-asserted-by":"crossref","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 2017 Aug :268-274. https:\/\/doi: 10.7326\/M16-2607.","DOI":"10.7326\/M16-2607"},{"key":"10.1016\/j.diabres.2026.113404_b0105","doi-asserted-by":"crossref","unstructured":"Butler J, Abildstr\u00f8m SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al.; Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2023;82:2087-96. https:\/\/doi: 10.1016\/j.jacc.2023.09.811.","DOI":"10.1016\/j.jacc.2023.09.811"},{"key":"10.1016\/j.diabres.2026.113404_b0110","doi-asserted-by":"crossref","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427-37. https:\/\/doi: 10.1056\/NEJMoa2410027.","DOI":"10.1056\/NEJMoa2410027"},{"key":"10.1016\/j.diabres.2026.113404_b0115","doi-asserted-by":"crossref","unstructured":"Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, et al.; STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022;327:138-50. https:\/\/doi: 10.1001\/jama.2021.23619.","DOI":"10.1001\/jama.2021.23619"},{"key":"10.1016\/j.diabres.2026.113404_b0120","doi-asserted-by":"crossref","unstructured":"Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, et al.;The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab 2020;22:1690-5. https:\/\/doi: 10.1111\/dom.14079.","DOI":"10.1111\/dom.14079"},{"key":"10.1016\/j.diabres.2026.113404_b0125","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.; REWIND Trial investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 2018;20:42-9. https:\/\/doi: 10.1111\/dom.13028.","DOI":"10.1111\/dom.13028"},{"key":"10.1016\/j.diabres.2026.113404_b0130","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al.; PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA 2019;321:1466-80. https:\/\/doi: 10.1001\/jama.2019.2942.","DOI":"10.1001\/jama.2019.2942"},{"key":"10.1016\/j.diabres.2026.113404_b0135","doi-asserted-by":"crossref","unstructured":"Gonzalez J, Dave CV. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021. BMC Cardiovasc Disord 2024;24:285. https:\/\/doi: 10.1186\/s12872-024-03961-5.","DOI":"10.1186\/s12872-024-03961-5"},{"key":"10.1016\/j.diabres.2026.113404_b0140","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA,et al.; DAPA-HF Trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. https:\/\/doi: 10.1056\/NEJMoa1911303.","DOI":"10.1056\/NEJMoa1911303"},{"key":"10.1016\/j.diabres.2026.113404_b0145","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020;383:1413-24. https:\/\/doi: 10.1056\/NEJMoa2022190.","DOI":"10.1056\/NEJMoa2022190"},{"key":"10.1016\/j.diabres.2026.113404_b0150","doi-asserted-by":"crossref","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D,et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404:773-86. https:\/\/doi: 10.1016\/S0140-6736(24)01498-3.","DOI":"10.1016\/S0140-6736(24)01498-3"},{"key":"10.1016\/j.diabres.2026.113404_b0155","doi-asserted-by":"crossref","unstructured":"Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, et al.; The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant 2023;38:2041-51. https:\/\/doi: 10.1093\/ndt\/gfad009. Erratum in: Nephrol Dial Transplant 2024;39:724. https:\/\/doi: 10.1093\/ndt\/gfad252.","DOI":"10.1093\/ndt\/gfad009"},{"key":"10.1016\/j.diabres.2026.113404_b0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure","volume":"109","author":"Ferreira","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2026.113404_b0165","unstructured":"Hu CS, Wu QH, Hu DY. Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications. J Thorac Dis 2014;6:1319-28. https:\/\/doi: 10.3978\/j.issn.2072-1439.2014.07.15."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:06:31Z","timestamp":1783458391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0168822726003244"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113404","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113404"}}